<DOC>
	<DOCNO>NCT01462604</DOCNO>
	<brief_summary>This 6-week , single arm , pilot study test study procedure , educational material , measurement instrument educational intervention HER2 overexpressing metastatic advanced breast cancer patient</brief_summary>
	<brief_title>Pilot Study Patient 's Adherence TYKERB™/TYVERB™ + Capecitabine Metastatic Breast Cancer</brief_title>
	<detailed_description>Approximately 60 subject HER2+ metastatic advance breast cancer meet inclusion/exclusion criterion enrol study . All subject receive education intervention 6 week include education Day 0 , follow-up phone call Day 1 Day 7 , reminder phone call Week 3 6 visit telephone hot line number .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Signed write informed consent ; 2 . Female outpatient age 18 year old ; 3 . Subjects must begin initial treatment lapatinib + capecitabine HER2+ metastatic advance breast cancer accord physician 's clinical judgement per local prescribe information 4 . Subjects must literate , able read , understand write local language . 1 . Women participate interventional clinical trial concurrently ; 2 . Women already take take lapatinib + capecitabine regimen prior enrollment ; 3 . Primary lesion breast origin .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>